 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | stannous protoporphyrin (RBT-9) / Renibus Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) (clinicaltrials.gov) - Mar 4, 2022
P2, N=42, Terminated, Sponsor: Renibus Therapeutics, Inc.
N=252 --> 42 | Trial completion date: Jun 2022 --> Sep 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2021; Enrollment feasibility
- ||| stannous protoporphyrin (RBT-9) / Renibus Therap
Enrollment closed: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) (clinicaltrials.gov) - Jan 6, 2022
P2, N=252, Active, not recruiting, Sponsor: Renibus Therapeutics, Inc.
N=252 --> 42 | Trial completion date: Jun 2022 --> Sep 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2021; Enrollment feasibility Recruiting --> Active, not recruiting
- || stannous protoporphyrin (RBT-9) / Renibus Therap
Trial completion date, Trial primary completion date: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) (clinicaltrials.gov) - Dec 2, 2021
P2, N=252, Recruiting, Sponsor: Renibus Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Dec 2021
- stannous protoporphyrin (RBT-9) / Renibus Therap
[VIRTUAL] RBT-9 Antiviral Activity Against BK Virus () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_3448;
The 50% cytotoxic concentration (CC 50 ) in the in vitro studies averaged 89.2 µM, indicating RBT-9 did not adversely affect host cell viability at concentrations 16.5 times higher than its effective concentration. Conclusion Given the antiviral activity of RBT-9 against BK virus in vitro and the safety profile of RBT-9 in Phase 1 human studies, a clinical study assessing the efficacy of RBT-9 is warranted in patients who are at risk of developing BK virus-induced nephropathy.
- || stannous protoporphyrin (RBT-9) / Renibus Therap
Trial completion: SnPP: A Study of RBT-9 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease (clinicaltrials.gov) - Nov 19, 2020
P1b, N=42, Completed, Sponsor: Renibus Therapeutics, Inc.
Conclusion Given the antiviral activity of RBT-9 against BK virus in vitro and the safety profile of RBT-9 in Phase 1 human studies, a clinical study assessing the efficacy of RBT-9 is warranted in patients who are at risk of developing BK virus-induced nephropathy. Active, not recruiting --> Completed
- stannous protoporphyrin (RBT-9) / Renibus Therap
[VIRTUAL] Design of PREVENT: A Phase 2 Study of the Effect of RBT-9 on Progression of COVID-19 Infection in High-Risk Individuals, Including Those with Advanced CKD (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1427;
The first patient is expected to be enrolled in June 2020. Funding: Commercial Support
- stannous protoporphyrin (RBT-9) / Renibus Therap
[VIRTUAL] Biomarker and Safety Results from a Phase 1b Study of RBT-9 in Healthy Volunteers and Subjects with CKD Stage 3/4 (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_612;
Adverse events were generally mild and related to photosensitivity reactions. Dose-dependent cytoprotective protein responses were observed that have previously corresponded with AKI protection in experimental animals.
- |||| stannous protoporphyrin (RBT-9) / Renibus Therap
Enrollment open: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) (clinicaltrials.gov) - Jul 7, 2020
P2, N=252, Recruiting, Sponsor: Renibus Therapeutics, Inc.
Dose-dependent cytoprotective protein responses were observed that have previously corresponded with AKI protection in experimental animals. Not yet recruiting --> Recruiting
- ||||| stannous protoporphyrin (RBT-9) / Renibus Therap
New P2 trial: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) (clinicaltrials.gov) - Apr 28, 2020
P2, N=252, Not yet recruiting, Sponsor: Renibus Therapuetics, Inc.
- | stannous protoporphyrin (RBT-9) / Renibus Therap
Trial completion date, Trial primary completion date: SnPP: A Study of RBT-9 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease (clinicaltrials.gov) - Apr 24, 2020
P1b, N=42, Active, not recruiting, Sponsor: Renibus Therapuetics, Inc.
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Jul 2020
- | stannous protoporphyrin (RBT-9) / Renibus Therap
New P1 trial: SnPP: A Study of RBT-9 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease (clinicaltrials.gov) - Aug 28, 2019
P1b, N=42, Active, not recruiting, Sponsor: Renibus Therapuetics, Inc.